An adaptive trial can add or drop arms, re-estimate sample sizes, or shift randomization ratios based on interim results — and an EDC system built primarily for fixed designs can technically capture that data while still creating real operational strain every time a design change actually happens. Large pharmaceutical organizations evaluating EDC systems for adaptive designs need a comparison framework built around that specific pressure point, not a general feature checklist.
What actually matters in this comparison
Mid-study eCRF flexibility. Can the system deploy updated eCRFs after an interim analysis without disrupting data already collected under the prior design, or does every design change require substantial rework?
Version control across active protocol states. Adaptive trials can have multiple protocol versions active simultaneously across cohorts. Data collected under earlier versions needs to stay usable and traceable, not treated as a disruptive migration each time.
Randomization that adjusts without compromising blinding. Response-adaptive randomization and sample re-estimation require allocation logic that can update mid-trial while preserving blinding integrity and a clear audit trail explaining every change.
Data availability for scheduled interim looks. Adaptive decisions depend on clean, current data being available on a defined interim analysis schedule — not whatever happens to be entered and cleaned through routine cycles by that point.
Audit trail depth covering design changes, not just data entry. A regulatory reviewer examining an adaptive trial needs to understand why and when the design changed, not just what data was collected. That history needs to be reconstructable directly from the system.
Comparison framework at a glance
| Evaluation Area |
Fixed-Design EDC |
Adaptive-Ready EDC |
| eCRF changes |
Requires substantial rework |
Supported without disrupting existing data |
| Version control |
Treats amendments as migrations |
Preserves multiple active versions |
| Randomization |
Static allocation |
Adjustable while preserving blinding |
| Interim data availability |
Routine cleaning cycles |
Available on the interim analysis schedule |
| Audit trail |
Explains data entry only |
Explains design change history too |
Why this matters under ICH E6(R3) and E9(R1)
ICH E6(R3) expects sponsors to maintain data integrity and oversight throughout the trial, and adaptive designs add real complexity to that expectation. ICH E9(R1), covering estimands and sensitivity analysis, reinforces that the rigor behind an adaptive decision needs to be as defensible as the underlying clinical data. An EDC that can't clearly document why and when a design change occurred puts that defensibility at risk.
How Cloudbyz EDC approaches this
Cloudbyz EDC is built with configurable eCRF and study design management intended to support mid-study changes without a full system rebuild for each amendment. Version history is preserved so data from earlier study versions stays usable and traceable, and because Cloudbyz builds EDC on the same platform as its broader eClinical suite, design-change history is positioned to stay connected to the same audit trail infrastructure regulatory reviewers rely on.
See how Cloudbyz EDC approaches adaptive trial design support book a demo with your own study structure.
Meeting at SCOPE Summit Europe? Our CEO, Dinesh Kashyap, will be in Barcelona on 13–14 October book time to talk this through.
